Lipodin-Ab™ is a protein transfection reagent dedicated to the transport of antibodies directly into living cells. Lipodin-Ab™ offers a new specific tool for studying molecular mechanisms in living cells by intracellular delivery of neutralizing or activating probes. Lipodin-Ab™ is a lipid-based formulation optimized for antibody delivery that is added to the antibody solution minutes before cell delivery. Within few hours, antibody staining can be observed in living or fixed cells. Regardless of serum addition, Lipodin-Ab™ is ideal for staining intracellular proteins without fixation in established cell lines and primary cells, including neurons.

Antibody Delivery Applications for Lipodin-Ab™

Lipodin-Ab can be used in various functional studies for cell signaling and apoptotic assays, protein-protein interaction, protein localization and compartment shuttling. When the antibody is conjugated to a fluorescent dye, the functional assay can be carried out in living cells under multiple treatments with a single sample.
Lipodin-Ab successfully delivered numerous antibodies in a wide variety of cells: monoclonal and polyclonal antibodies from human, mouse, rabbit and rat origins, unconjugated or labeled with FITC, TRITC, AlexaFluor®488 and AlexaFluor®546. Standard cell lines (CHO, COS-7, HEK-293, HeLa, NIH3T3) and primary cells (neurons, glial cells) were successfully assayed for Lipodin-Ab reagent.

Antibody Delivery Experiments using Lipodin-Ab™

(A) Human IgG labeled with FITC (1 μg) was delivered in monkey kidney fibroblast COS-7 cells and fluorescence observed 4 h post-transfection.

(B) An antibody conjugated to AlexaFluor®488 (0.5 μg) was delivered in primary neurons and glial cells. Fluorescence was observed 24 h post-transfection.

(C) An anti-Nuclear Pore Complex antibody conjugated to AlexaFluor®488 (0.5 μg) was delivered in human non-small cell lung carcinoma A549 cells and the nuclear envelope localization (white arrow) observed 6 h post-transfection.

(D) An anti-Nuclear Pore Complex antibody (0.5 μg) was delivered in hamster ovary epithelial CHO cells and apoptotic effect observed 72 h post-transfection. Control cells transfected with Lipodin-Ab alone are shown in inset.

Lipodin-Ab™ Advantages over Current Antibody Delivery Techniques

• Unique reagent dedicated to antibody
• No need for cell fixation protocol
• Serum compatible, no cytotoxicity and biodegradable
• Easy 2-step protocol with ready-to-use reagents
• Deliver functionally active antibody within hours
• High delivery efficiency with stable cell lines and primary cells

How Lipodin-Ab™ Works

Lipodin-Ab is an optimized formulation of lipids able to capture antibodies through electrostatic and hydrophobic interactions. There is no need for covalent linkage procedure, Lipodin-Ab is directly mixed with the antibody of interest for 10 minutes. The mixture is then added to the cells in culture, the lipid-antibody complexes are internalized by the cells and the antibodies are released into the cytoplasm within few hours without any cytotoxicity. The formulation of Lipodin-Ab is fully biodegradable maintaining high cell viability upon delivery. The antibodies delivered inside the cells with Lipodin-Ab retain both their structure and function.

How to Order Lipodin-Ab™

Contents and Storage

Lipodin-Ab™ antibody delivery reagent is offered in 25- and 100-reaction kits, for which a reaction is defined as the amount of reagents required to deliver 2 μg of FITC-labeled IgG positive control antibody to cells in one well of a 12-well plate. The number of reactions varies depending on the plate size and type of macromolecule to deliver. Each kit includes the Lipodin-Ab antibody delivery reagent, a FITC-labeled IgG solution as positive control, and a comprehensive instruction manual. Kit components are shipped at room temperature and stored at 4°C upon receiving. Components are guaranteed stable for one year.

Citations

Wu J et al. 2016. Sci Rep. 6: 33382. PMID 27633136.

Koley D et al. 2012. Proc Natl Acad Sci USA. 109(29): 11522-7. PMID 22679290

Lin T et al. 2010. Urologic Oncology: Seminars and Original Investigations. 30(3):339-345. PMID 20843711